



HY24 Financial Results and Business Highlights

22 August 2024



Your speakers today



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer



Carlo Boutton
Chief Scientific Officer

Agenda

- HY 24 business highlights
 - AgTech Breakthrough Award 2024
 - Regulatory update
 - R&D update
- HY 24 financial results
- Outlook
- Q&A



Disclaimer



This presentation, including the oral presentation (together, the “Materials”) has been prepared by the management of Biotallys NV (the “Company”). The Materials must be treated confidentially and may not be distributed, passed on or otherwise disclosed. The Materials serve information purposes only and do not constitute a prospectus or any offer for sale or subscription of, or solicitation or invitation to buy or subscribe for, any securities of the Company. The Company’s business, operations, financial situation and prospects are subject to risks and uncertainties. A description of the most important risks and uncertainties can be found in the Company’s annual report available on its website (www.Biotallys.com)

This presentation includes market share and industry data, which were obtained by the Company from industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers and internal surveys. The third party sources the Company has used generally state that the information they contain has been obtained from sources believed to be reliable. Some of these third party sources also state, however, that the accuracy and completeness of such information is not guaranteed and that the projections they contain are based on significant assumptions. As the Company does not have access to the facts and assumptions underlying such market data, or statistical information and economic indicators contained in these third party sources, the Company is unable to verify such information and, while the Company believes it to be reliable, it cannot guarantee its accuracy or completeness.

In addition, certain information in this document is not based on published data obtained from independent third parties or extrapolations therefrom, but rather is based upon the Company’s best estimates, which are in turn based upon information obtained from trade and business organizations and associations, consultants and other contacts within the industries in which the Company operates, information published by its competitors and its own experience and knowledge of conditions and trends in the markets in which it operates. The Company cannot provide any assurance that any of the assumptions that it has made while compiling this data from third party sources are accurate or correctly reflect its position in the industry and none of its internal estimates have been verified by any independent sources. The Company makes no representation or warranty as to the accuracy or completeness of this information. The Company has not independently verified this information and, while the Company believes it to be reliable, it cannot guarantee its accuracy.

You are responsible for protecting yourself against viruses and other destructive items. You are accessing the Materials is at your own risk and it is your responsibility to take precautions to ensure that they are free from viruses or other items of a destructive nature.

The Materials are provided in conjunction with the oral presentation held by the Company and should not be taken out of context.

The information contained in the Materials is subject to change without prior notice. The presentation of the Materials (or any part hereof) shall not create any implication that there has been no change in the information contained in the Materials since the date hereof or that there has been no change in the business or financial position of the Company or its subsidiary since the date hereof. The Company does not undertake to provide any additional information, update or keep current information contained in the Materials, or to remedy any omissions in or from the Materials and any opinions expressed in the Materials are subject to change without prior notice. The foregoing is in any event without prejudice to the Company’s obligations under applicable law in relation to disclosure.

The Materials contain certain forward-looking statements, sometimes identified by the words “believes,” “expects,” “predicts,” “intends,” “projects,” “plans,” “estimates,” “aims,” “foresees,” “anticipates,” “targets,” and similar expressions, which speak only as at the date of the Materials. Such statements reflect current views with respect to future events and are subject to risks and uncertainties. Forward-looking statements are based on current plans, estimates, projections and expectations. These statements are based on certain assumptions that may prove to be erroneous. No representations or warranties, express or implied, are given as to the achievement or reasonableness of, and no reliance should be placed on, such forward-looking statements, including any projections, estimates forecasts or targets contained herein.

Nothing in this presentation constitutes an offer of securities for sale in the EEA, the United Kingdom, Switzerland, Japan, the United States or elsewhere. The securities of the Company are not registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered, sold or otherwise transferred within the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration. There is no intention to register securities of the Company under the Securities Act.

You acknowledge that all industrial and intellectual property rights to this presentation are and shall remain vested in the Company. By attending this presentation or accessing the Materials you shall not acquire any right, title, license to use, or interest in the presentation or the Materials.

All of the trademarks, service marks and logos displayed in the Materials, including but not limited to Biotallys, AGROBODY, EVOCA are registered and unregistered trademarks of the Company or one of its affiliates. Except as expressly provided in the Materials, you may not reproduce, display or otherwise use trademarks without first obtaining the Company’s written permission.

Biotallys and each of their logos are commercial names, trademarks or registered trademarks owned by Biotallys NV.

Kevin Helash, CEO




Biotallys wins AgTech Breakthrough Award 2024

- Biotallys named **Sustainable Crop Protection Company of the Year**
- AgTech Breakthrough Awards recognize the best agricultural and food technology companies, products and services around the globe
- This year's AgTech awards program attracted over 1,000 nominations from all over the world for the different categories

**Biotallys
Named 2024
Sustainable
Crop Protection
Company of
the Year**



Biotalys is set to enter the market, fully prepared for commercial deployment



The Biotalys and Novonesis partnership unleashes production breakthroughs, propelling to commercialization



- ⊕ **EVOCA NG** is advanced to the **final stage of development together with Novonesis**, a global leader in biosolutions
- ⊕ **Novonesis** is appointed as **global manufacturer** of EVOCA NG, leveraging its key fermentation capabilities
- ⊕ **Novonesis** and Biotalys will co-commercialize EVOCA NG, with Novonesis covering all markets in Europe and South Africa (outside of covered crops and field berries), with potential other markets
- ⊕ Biotalys and Novonesis will **explore future collaborations** involving the AGROBODY™ technology platform in combination with their proprietary enzyme platform

Regulatory update

Ongoing regulatory review in the U.S. and Europe, while exploring options to submit in other regions

U.S.

- Dialogue with the EPA is ongoing while the authority's review is progressing. Biotalys has not received additional questions in 2024.
- Biotalys is preparing the regulatory dossier for EVOCA NG to be submitted under the shorter amendment procedure after EVOCA is approved.

EU:

- Biotalys received additional questions from the CTGB – the Dutch regulatory from the rapporteur member state the Netherlands. Biotalys plans to submit answers still in the coming weeks.
- CTGB approved large-scale demonstration trials allowing sale of harvest for human consumption
- Biotalys is preparing the regulatory dossier for EVOCA NG to be submitted under the shorter equivalency procedure after EVOCA is approved.



Multiple strategic options for collaboration monetization



Deal structure customized to partner capabilities, resources and interests, resulting in either more front or back loaded deals





Note 1. : Biotalsys further explores a broad range of partnerships along the food value chain with established players including at crop protection and around/post harvest stages

Carlo Boutton, CSO



Potential to unleash an array of combinations of different MoAs, opening up major market growth vectors



Biotallys is developing +10 different modes of action in the next decade, with the potential to combine these MoAs into different products and offer a multitude of unique AGROBODY biocontrol solutions by then













Source: Data based on company's own estimates

AlphaFold




- Project together with Google DeepMind and Devoteam to set up **AlphaFold2**, an AI platform developed to discover the precise 3D shapes of proteins, the building blocks of nature.
- With its **AGROBODY 2.0** technology platform, Biotallys applies a **targeted approach** requiring the detailed characterization of target proteins of the fungal diseases or pests. AlphaFold2 predicts the 3D shapes of these proteins, enabling Biotallys to better validate these and improve the speed and quality of its R&D workflow.
- This is expected to ultimately result in an **accelerated discovery process** of AGROBODY™ bioactives and **faster delivery of novel biocontrols** to the market.



Innovative pipeline of biofungicides and bioinsecticides

Program	Target	Market	Discovery	Early Development	Late Development	Registration	Partnership Agreement
 EVOCA 1st Gen	Botrytis, powdery mildew	High-value fruits & vegetables	●	●	●	---  <i>Pilot product</i>	 <small>SUSTAINABLE CROP MANAGEMENT</small>
 EVOCA Next Gen	Botrytis, powdery mildew	High-value fruits & vegetables	●	●	●		  <small>SUSTAINABLE CROP MANAGEMENT</small>
 BioFun-6	Botrytis, powdery mildew, Anthracnosis	High-value fruits & vegetables	●	→			Discussions ongoing
 BioFun-7	Cercospora spp. (leafspot disease)	Cowpeas and other legumes	●	→			 <small>BILL & MELINDA GATES foundation</small>
 BioFun-4	Oomycetes (water mold)	Potatoes / High-value fruits & vegetables	●	→			Discussions ongoing
 BioIns-2	Key insect pests	Non-disclosed	●	→			

1 new program per year resulting in +10 AGROBODY biocontrols to be launched on the market between 2025 and 2040

 Distribution agreement
  Manufacturing agreement
  Research agreement

Douglas Minder, CFO



Key financials – HY 2024

In € thousand	June 30, 2024	June 30, 2023
Other operating income	1,452	1,318
Research and development expenses	(5,135)	(8,661)
General and administration expenses	(2,777)	(2,771)
Marketing expenses	(113)	(741)
Operating loss	(6,574)	(10,855)
Loss of the period	(6,489)	(10,664)
Net cash used in operations	(6,527)	(8,516)
Net cash outflow for the period	(6,890)	(2,208)
Cash and cash equivalents	14,680	31,886

Outlook: key milestones ahead



EVOCA™ Registration

- Obtain product approval for EVOCA in the U.S. & Europe, while finalizing EVOCA NG together with Novonosis



AGROBODY Foundry™ 2.0

- Leverage platform to secure further strategic crop protection R&D collaborations
- Upgrade platform capabilities towards exponential potency and costs targets



Commercial Agreements

- Explore partnership agreements for BioFun-6 and post-harvest applications



Funding

- Secure additional funding to extend the company's runway

Q&A



Kevin Helash
Chief Executive Officer



Douglas Minder
Chief Finance Officer



Carlo Boutton
Chief Scientific Officer



biotaly
reinventing food protection